Table 4.
The overall treatment effectiveness and according to treatment regimens in relation to different risk factors among the studied patients (per protocol analysis)
|
Parameter
|
Whole population
|
Females
|
Males
|
F4
|
T-ex
|
History of hepatic decompensation
|
≥ 70-year-old
|
eGFR ≤ 60 mL/min
|
Obese
1
|
HIV+
|
| All regimens | 10903/11112 (98.1) | 5891/5969 (98.7) | 5012/5143 (97.5) | 2590/2678 (96.7) | 2726/2795 (97.5) | 319/336 (94.9) | 1490/1509 (98.7) | 281/284 (98.9) | 1880/1923 (97.8) | 327/341 (95.9) |
| ASV + DCV | 119/132 (90.2) | 72/79 (91.1) | 47/53 (88.7) | 47/55 (85.5) | 40/47 (85.1) | 0/1 (0) | 22/24 (91.7) | 5/5 (100) | 26/28 (92.9) | 1/1 (100) |
| LDV/SOF ± RBV | 2534/2582 (98.1) | 1381/1398 (98.8) | 1153/1184 (97.4) | 679/707 (96) | 680/696 (97.7) | 173/181 (95.6) | 386/389 (99.2) | 67/67 (100) | 446/459 (97.2) | 103/107 (96.3) |
| OBV/PTV/r + DSV ± RBV | 3563/3627 (98.2) | 1949/1973 (98.8) | 1614/1654 (97.6) | 969/992 (97.7) | 1490/1516 (98.3) | 72/74 (97.3) | 397/403 (98.5) | 80/82 (97.6) | 602/611 (98.5) | 26/28 (92.9) |
| GZR/EBR ± RBV | 2179/2216 (98.3) | 1201/1215 (98.8) | 978/1001 (97.7) | 362/372 (97.3) | 291/297 (98) | 19/20 (95) | 397/401 (99) | 87/88 (98.9) | 380/389 (97.7) | 48/48 (100) |
| GLE/PIB | 1625/1643 (98.9) | 869/874 (99.4) | 756/769 (98.3) | 264/268 (98.5) | 112/114 (98.2) | 12/12 (100) | 147/150 (98) | 24/24 (100) | 267/267 (100) | 72/76 (94.7) |
| GLE/PIB + SOF + RBV | 3/3 (100) | 1/1 (100) | 2/2 (100) | 1/1 (100) | 3/3 (100) | - | - | - | 1/1 (100) | - |
| SOF/VEL ± RBV | 857/884 (96.9) | 409/419 (97.6) | 448/465 (96.3) | 260/275 (94.5) | 91/101 (90.1) | 40/44 (90.9) | 138/139 (99.3) | 16/16 (100) | 158/167 (94.6) | 74/78 (94.9) |
| VOX/VEL/SOF | 9/9 (100) | 2/2 (100) | 7/7 (100) | 3/3 (100) | 7/7 (100) | - | 3/3 (100) | - | - | 3/3 (100) |
1
Body mass index > 30 kg/m2.
Data are presented as number/total number of patients (percentage). ASV: Asunaprevir; DCV: Daclatasvir; DSV: Dasabuvir; EBR: Elbasvir; eGFR: Estimated glomerular filtration rate; F: Fibrosis; GLE: Glecaprevir; GZR: Grazoprevir; HIV: Human immunodeficiency virus; LDV: Ledipasvir; OBV: Ombitasvir; PIB: Pibrentasvir; PP: Per protocol; PTV/r: Paritaprevir; RBV: Ribavirin; SOF: Sofosbuvir; SVR: Sustained virological response; T-ex: Treatment-experience; VEL: Velpatasvir; VOX: Voxilaprevir.